Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
15.245
Zitationen
29
Autoren
2020
Jahr
Abstract
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Ähnliche Arbeiten
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
2020 · 51.542 Zit.
Clinical Characteristics of Coronavirus Disease 2019 in China
2020 · 31.035 Zit.
A Novel Coronavirus from Patients with Pneumonia in China, 2019
2020 · 30.164 Zit.
A pneumonia outbreak associated with a new coronavirus of probable bat origin
2020 · 23.170 Zit.
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
2020 · 22.609 Zit.
Autoren
- Fernando P. Polack
- Stephen J. Thomas
- Nicholas Kitchin
- Judith Absalon
- Alejandra Gurtman
- Stephen Lockhart
- John L. Perez
- Gonzalo Pérez Marc
- Edson Duarte Moreira
- Cristiano A. F. Zerbini
- Ruth Bailey
- Kena A. Swanson
- Satrajit Roychoudhury
- Kenneth Koury
- Ping Li
- Warren V. Kalina
- David Cooper
- Robert W. Frenck
- Laura L Hammitt
- Özlem Türeci
- Haylene Nell
- Axel Schaefer
- Serhat Ünal
- Dina B Tresnan
- Susan Mather
- Philip R. Dormitzer
- Uğur Şahin
- Kathrin U. Jansen
- William C. Gruber